Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA
The high-throughput system enables laboratories to double or even triple their testing capacity
The partnership enables LUMICKS to expand on the implementation of the z-Movi to new immunotherapeutic settings
The new reagent kits aim to make whole genome sequencing more accessible and affordable for labs of all sizes
This powerful new solution aims to provide more accurate COVID-19 antibody detection
Join us on Tuesday, August 11, to learn about a novel serological platform used for COVID-19 testing
Join us on Monday, August 17, to discover solutions for your laboratory's SARS-CoV-2 testing
Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva
Vanderbilt researchers use high-throughput data collection, analysis, and visualization to help understand synergy in therapeutic antibody cocktails
BLENREP is the fifth major medicine approval for GSK in 2020
With this numerical result expressed as index value, clinicians will be better equipped to evaluate the duration and level of an individual’s immune response
Exclusive interviews, new methods, free downloads, and much more to help you advance your work
California Laboratories can now instantly transmit covid-19 data to the CalREDIE system
Rapid antibody test receives CE mark for use by healthcare professionals
University of California San Francisco (UCSF) uses Phenoptics™ platform to help with biomarker discovery
TrueBinding signs multi-product commercial-use license to develop stable, antibody-expressing cell lines using Horizon’s gene-edited CHO GS knockout platform
Developed with enhanced technology, this new assay provides high-quality staining with improved turnaround time
The study is the first global, randomized, double-blind, placebo-controlled phase III trial investigating Actemra/RoActemra in this setting
Find out how LC-MS technology is being used to quantify the experimental drug remdesivir
